Genus/£GNS
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Genus
Genus PLC, trading under the ticker GNS on the London Stock Exchange, specializes in animal genetics and biotechnology. The company, founded in 1994 and headquartered in Basingstoke, United Kingdom, operates across multiple countries offering genetically superior pig and cattle breeding stock along with state-of-the-art in vitro fertilization products. Genus PLC aims to empower customers in the livestock sector to enhance the efficiency and profitability of their operations by providing innovative genetic solutions and services.
Ticker
£GNS
Sector
Primary listing
LSE
Employees
3,500
Headquarters
Website
Genus Metrics
BasicAdvanced
£1.7B
86.85
£0.29
0.58
£0.32
1.27%
Price and volume
Market cap
£1.7B
Beta
0.58
52-week high
£32.29
52-week low
£14.24
Average daily volume
134K
Dividend rate
£0.32
Financial strength
Current ratio
1.938
Quick ratio
1.272
Long term debt to equity
52.458
Total debt to equity
55.861
Dividend payout ratio (TTM)
109.33%
Interest coverage (TTM)
3.10%
Profitability
EBITDA (TTM)
91.5
Gross margin (TTM)
100.00%
Net profit margin (TTM)
2.87%
Operating margin (TTM)
10.15%
Effective tax rate (TTM)
32.28%
Revenue per employee (TTM)
£190,000
Management effectiveness
Return on assets (TTM)
4.43%
Return on equity (TTM)
3.78%
Valuation
Price to earnings (TTM)
86.851
Price to revenue (TTM)
2.459
Price to book
3.48
Price to tangible book (TTM)
5.22
Price to free cash flow (TTM)
34.04
Free cash flow yield (TTM)
2.94%
Free cash flow per share (TTM)
0.737
Dividend yield (TTM)
1.27%
Growth
Revenue change (TTM)
0.60%
Earnings per share change (TTM)
142.86%
3-year revenue growth (CAGR)
4.27%
10-year revenue growth (CAGR)
5.38%
3-year earnings per share growth (CAGR)
-22.55%
10-year earnings per share growth (CAGR)
-7.77%
10-year dividend per share growth (CAGR)
5.08%
What the Analysts think about Genus
Analyst ratings (Buy, Hold, Sell) for Genus stock.
Bulls say / Bears say
Genus received FDA approval for its PRRS-Resistant Pig (PRP) gene edit in April 2025, triggering a £3.7 million milestone payment and setting the stage for faster growth from fiscal 2027.
In its FY25 trading update, Genus reported double-digit underlying growth in its PIC pig breeding unit and, including the PRP milestone, increased its adjusted profit before tax outlook to at least £72 million.
ABS cattle genetics beat expectations in the second half of FY25, with Phase 2 of the Value Acceleration Programme delivering £8.5 million in annual benefits, supporting higher margins and cash flow.
PRP won’t make a significant contribution to Genus’s income statement until fiscal 2027, so revenue growth from the key gene-edited pig program will be delayed.
Retaliatory export tariffs could restrict U.S. pork sales to major markets such as Japan, Canada, and Mexico, potentially limiting the commercial launch of Genus’s PRP gene-edited pigs.
Ongoing pork oversupply and weak prices in China—Genus’s largest royalty market—are squeezing producer margins and could hurt profitability and royalty growth for the PIC division.
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
Genus Financial Performance
Revenues and expenses
Genus Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
Nov6
Genus
DividendEx-dividend
Dec5
Genus
DividendPayment
£0.217Per share
FAQs
What’s the current market cap for Genus stock?
Genus (GNS) has a market cap of £1.7B as of September 16, 2025.
What is the P/E ratio for Genus stock?
The price to earnings (P/E) ratio for Genus (GNS) stock is 86.85 as of September 16, 2025.
Does Genus stock pay dividends?
Yes, the Genus (GNS) stock pays dividends to shareholders. As of September 16, 2025, the dividend rate is £0.32 and the yield is 1.27%. Genus has a payout ratio of 109.33% on a trailing twelve-month basis.
When is the next Genus dividend payment date?
The next Genus (GNS) dividend payment is scheduled for December 05, 2025.
What is the beta indicator for Genus?
Genus (GNS) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.